logo-loader
viewArix Bioscience PLC

Arix Bioscience edges higher after positive news from one of its portfolio companies

Arix is a global venture capital company focused on investing in and building breakthrough biotech companies

Arix Bioscience PLC -

Biotech companies backer Arix Bioscience PLC (LON:ARIX) said one of its investment companies - Amplyx – has published positive results from a phase 2 study.

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, had positive news about its lead programme, APX001 (fosmanogepix), a treatment for the yeast infection, candidemia.

Amplyx said that two independent review committees have completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Phase 2 open-label clinical trial of APX001.

The Data Review Committee adjudicated that fosmanogepix demonstrated a high level of treatment success at the end of study drug treatment.

The Data Safety Monitoring Board recommended that the study continues according to the protocol. The Phase 2 study will continue to enrol patients, with a planned total of 20 patients by the end of the year, across sites in the United States, Europe and Israel.

“These initial clinical trial results represent the first efficacy data in patients and support the highly differentiated profile of fosmanogepix for the treatment of serious fungal infections, representing an important milestone for the fosmanogepix Phase 2 candidemia study,” said Ciara Kennedy, the president and chief executive officer of Amplyx.

Amplyx also announced that it has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868, for the treatment and prevention of BKV disease, from drugs giant, Novartis.

The company is planning two Phase 2 proof-of-concept clinical trials of MAU868 in BKV disease.

“The addition of MAU868 to the Amplyx pipeline leverages the company’s significant experience from fosmanogepix (APX001),” Kennedy said.

“We anticipate starting Phase 2 trials in the near future and, longer-term, developing MAU868 as the first antiviral drug for BKV disease,” Kennedy added.

Shares in Arix were up 0.4% at 120.5p.

Quick facts: Arix Bioscience PLC

Price: 110.8 GBX

LSE:ARIX
Market: LSE
Market Cap: £153.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read